Innoviva, Inc. (NASDAQ:INVA) received a $16.00 price target from Cowen and Company in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cowen and Company’s price objective would indicate a potential upside of 15.69% from the company’s current price.

Several other equities research analysts have also commented on the company. Zacks Investment Research lowered Innoviva from a “hold” rating to a “sell” rating in a research note on Monday, July 3rd. ValuEngine lowered Innoviva from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Stifel Nicolaus restated a “neutral” rating on shares of Innoviva in a research note on Friday, September 15th. Morgan Stanley restated an “underweight” rating and issued a $8.00 price objective (up from $7.00) on shares of Innoviva in a research note on Friday, October 6th. Finally, Robert W. Baird restated a “neutral” rating and issued a $13.00 price objective (up from $11.00) on shares of Innoviva in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $13.60.

Shares of Innoviva (INVA) traded up 0.87% during trading on Monday, hitting $13.95. The stock had a trading volume of 711,694 shares. Innoviva has a 1-year low of $8.67 and a 1-year high of $14.87. The stock’s 50-day moving average price is $13.96 and its 200 day moving average price is $13.00. The firm has a market capitalization of $1.53 billion, a P/E ratio of 17.55 and a beta of 2.60.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.28 by $0.02. The firm had revenue of $58.60 million during the quarter, compared to analyst estimates of $50.53 million. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. Innoviva’s revenue was up 80.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.13 EPS. On average, analysts anticipate that Innoviva will post $1.15 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Reiterates “$16.00” Price Target for Innoviva, Inc. (INVA)” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/24/cowen-and-company-reiterates-16-00-price-target-for-innoviva-inc-inva.html.

Hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its stake in Innoviva by 68,215.3% in the 1st quarter. BlackRock Inc. now owns 12,000,259 shares of the biotechnology company’s stock worth $165,964,000 after buying an additional 11,982,693 shares in the last quarter. Morgan Stanley increased its stake in Innoviva by 92.2% in the 1st quarter. Morgan Stanley now owns 564,427 shares of the biotechnology company’s stock worth $7,807,000 after buying an additional 270,824 shares in the last quarter. Federated Investors Inc. PA increased its stake in Innoviva by 9.2% in the 2nd quarter. Federated Investors Inc. PA now owns 121,499 shares of the biotechnology company’s stock worth $1,555,000 after buying an additional 10,269 shares in the last quarter. KCG Holdings Inc. increased its stake in Innoviva by 63.9% in the 1st quarter. KCG Holdings Inc. now owns 30,265 shares of the biotechnology company’s stock worth $419,000 after buying an additional 11,802 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Innoviva in the 2nd quarter worth $730,000. Institutional investors and hedge funds own 69.72% of the company’s stock.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.